United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $955,728.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction on Monday, May 13th. The stock was sold at an average price of $265.48, for a total value of $955,728.00. Following the sale, the chief executive officer now owns 130 shares of the company's stock, valued at $34,512.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

United Therapeutics Stock Performance

NASDAQ UTHR traded up $5.44 during trading hours on Tuesday, reaching $269.78. The stock had a trading volume of 389,190 shares, compared to its average volume of 462,249. The stock has a fifty day moving average of $241.23 and a 200 day moving average of $230.97. The stock has a market cap of $11.97 billion, a P/E ratio of 12.50 and a beta of 0.54. United Therapeutics Co. has a 52-week low of $204.44 and a 52-week high of $269.83. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.64 and a current ratio of 3.77.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, beating analysts' consensus estimates of $5.63 by $0.54. The firm had revenue of $677.70 million for the quarter, compared to analyst estimates of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. United Therapeutics's revenue for the quarter was up 33.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $4.86 earnings per share. Sell-side analysts predict that United Therapeutics Co. will post 24.2 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. SVB Leerink assumed coverage on United Therapeutics in a report on Monday, February 5th. They issued an "outperform" rating and a $330.00 price objective for the company. Wedbush restated an "outperform" rating and issued a $308.00 price objective on shares of United Therapeutics in a report on Thursday, February 22nd. StockNews.com downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Thursday, April 11th. Wells Fargo & Company lifted their price objective on United Therapeutics from $309.00 to $325.00 and gave the company an "overweight" rating in a report on Thursday, March 7th. Finally, Oppenheimer lifted their target price on United Therapeutics from $375.00 to $400.00 and gave the company an "outperform" rating in a research note on Thursday, May 2nd. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $308.78.

Institutional Investors Weigh In On United Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Norges Bank acquired a new stake in United Therapeutics during the fourth quarter valued at $100,519,000. Nordea Investment Management AB grew its position in United Therapeutics by 677.6% during the first quarter. Nordea Investment Management AB now owns 300,920 shares of the biotechnology company's stock valued at $72,422,000 after buying an additional 262,222 shares during the period. Avidity Partners Management LP acquired a new stake in shares of United Therapeutics in the fourth quarter valued at about $52,158,000. LSV Asset Management grew its position in shares of United Therapeutics by 40.3% in the first quarter. LSV Asset Management now owns 529,519 shares of the biotechnology company's stock valued at $121,641,000 after purchasing an additional 152,151 shares during the period. Finally, Comerica Bank boosted its position in United Therapeutics by 2,697.2% during the third quarter. Comerica Bank now owns 156,587 shares of the biotechnology company's stock worth $35,368,000 after acquiring an additional 150,989 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.